drugset / Trial / NCT02577029
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be evaluated for safety and efficacy.
Timeline
- Start
- 2015-12
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARC-520 | Unknown | 2 mg/kg | Intravenous |
| Subject | ARC-520 | Unknown | 4 mg/kg | Intravenous |
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |